Bionime Corporation (TPE:4737)
Taiwan
· Delayed Price · Currency is TWD 62.70
-0.30 (-0.48%)
Apr 29, 2026, 1:30 PM CST
Bionime Income Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Revenue | 1,839 | 1,934 | 1,756 | 2,211 | 1,850 | Upgrade
|
| Revenue Growth (YoY) | -4.92% | 10.15% | -20.58% | 19.50% | 10.87% | Upgrade
|
| Cost of Revenue | 1,211 | 1,165 | 1,040 | 1,206 | 1,067 | Upgrade
|
| Gross Profit | 627.81 | 768.38 | 715.65 | 1,004 | 783.13 | Upgrade
|
| Selling, General & Admin | 476.3 | 575.11 | 523.17 | 641.15 | 540.54 | Upgrade
|
| Research & Development | 354.76 | 322.33 | 242.34 | 201.98 | 187.86 | Upgrade
|
| Operating Expenses | 825.17 | 923.57 | 728.99 | 872.71 | 707.84 | Upgrade
|
| Operating Income | -197.36 | -155.19 | -13.34 | 131.42 | 75.29 | Upgrade
|
| Interest Expense | -64.9 | -62.19 | -48.23 | -30.65 | -19.05 | Upgrade
|
| Interest & Investment Income | 6.25 | 5.05 | 4.32 | 0.94 | 0.71 | Upgrade
|
| Currency Exchange Gain (Loss) | 6.99 | 7.41 | 5.24 | -14.96 | 0.94 | Upgrade
|
| Other Non Operating Income (Expenses) | 12.13 | 23.27 | 20.15 | 3.92 | 16.7 | Upgrade
|
| EBT Excluding Unusual Items | -236.89 | -181.66 | -31.86 | 90.67 | 74.6 | Upgrade
|
| Gain (Loss) on Sale of Investments | - | - | - | -0.01 | - | Upgrade
|
| Gain (Loss) on Sale of Assets | -3.07 | -0.08 | -0.01 | -4.17 | -0 | Upgrade
|
| Asset Writedown | -9.45 | -3.98 | - | - | - | Upgrade
|
| Other Unusual Items | - | - | - | - | -0.01 | Upgrade
|
| Pretax Income | -249.41 | -185.71 | -31.88 | 86.48 | 74.59 | Upgrade
|
| Income Tax Expense | -70.09 | -59.71 | -38.41 | -5.34 | -14.74 | Upgrade
|
| Earnings From Continuing Operations | -179.32 | -126 | 6.53 | 91.82 | 89.33 | Upgrade
|
| Minority Interest in Earnings | -0.96 | -1.22 | -0.32 | -0.8 | -1.91 | Upgrade
|
| Net Income | -180.28 | -127.22 | 6.21 | 91.03 | 87.41 | Upgrade
|
| Net Income to Common | -180.28 | -127.22 | 6.21 | 91.03 | 87.41 | Upgrade
|
| Net Income Growth | - | - | -93.18% | 4.13% | 40.01% | Upgrade
|
| Shares Outstanding (Basic) | 67 | 67 | 67 | 67 | 66 | Upgrade
|
| Shares Outstanding (Diluted) | 67 | 67 | 67 | 68 | 67 | Upgrade
|
| Shares Change (YoY) | 0.18% | -0.44% | -0.28% | 0.98% | 0.75% | Upgrade
|
| EPS (Basic) | -2.68 | -1.90 | 0.09 | 1.37 | 1.32 | Upgrade
|
| EPS (Diluted) | -2.68 | -1.90 | 0.09 | 1.35 | 1.31 | Upgrade
|
| EPS Growth | - | - | -93.25% | 2.78% | 39.80% | Upgrade
|
| Free Cash Flow | 338.62 | -166.55 | -89.64 | 4.62 | 132.25 | Upgrade
|
| Free Cash Flow Per Share | 5.04 | -2.48 | -1.33 | 0.07 | 1.98 | Upgrade
|
| Dividend Per Share | - | - | 1.818 | 1.909 | 1.818 | Upgrade
|
| Dividend Growth | - | - | -4.76% | 5.03% | -3.06% | Upgrade
|
| Gross Margin | 34.15% | 39.73% | 40.77% | 45.42% | 42.33% | Upgrade
|
| Operating Margin | -10.73% | -8.03% | -0.76% | 5.95% | 4.07% | Upgrade
|
| Profit Margin | -9.80% | -6.58% | 0.35% | 4.12% | 4.72% | Upgrade
|
| Free Cash Flow Margin | 18.42% | -8.61% | -5.11% | 0.21% | 7.15% | Upgrade
|
| EBITDA | -41.96 | 0.65 | 128.13 | 267.54 | 213.85 | Upgrade
|
| EBITDA Margin | -2.28% | 0.03% | 7.30% | 12.10% | 11.56% | Upgrade
|
| D&A For EBITDA | 155.4 | 155.84 | 141.47 | 136.12 | 138.55 | Upgrade
|
| EBIT | -197.36 | -155.19 | -13.34 | 131.42 | 75.29 | Upgrade
|
| EBIT Margin | -10.73% | -8.03% | -0.76% | 5.95% | 4.07% | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.